Kevin Fitzgerald Email Address

Chief Scientific Officer

Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hemophilia, and porphyria.

Patient-centric executive with career marked by developing drugs that impact disease progression and outcomes, while leveraging novel technologies in development process. Data-driven leader skilled in building relationships with staff, team members, alliance partners, and key opinion leaders. Proven success in drug development and delivery spanning small molecule, oligonucleotide, nanoparticles, liposomes, and conjugates. Accomplished public speaker, published author, and patent holder Expertise in orphan disease drug development, oncology, metabolic diseases, human genetics, and complex drug delivery.